As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. Sen. Elizabeth Warren, D-Massachusetts, sent a letter (PDF) to the chair of the U.S. Federal Trade Commission (FTC), Lina Khan, calling on the antitrust agency to “carefully scrutinize” the multibillion-dollar merger—and to block it if necessary under U.S. competition laws. “I am concerned that this deal could increase Novo Nordisk’s dominance over vital GLP-1 inhibitor drugs, reducing competition and increasing prices for patients,” Warren wrote.
Read the full article: Warren Calls on FTC to Scrutinize Novo Holdings’ $16.5B Catalent Buyout //
Source: https://www.fiercepharma.com/pharma/sen-warren-sets-sights-novo-holdings-proposed-165b-catalent-acquisition-deal-nears